Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGLEC7 | Q9Y286 | 6/20 | 0.68 |
| ▸ | MAG | P20916 | 9/20 | 0.67 |
| ▸ | SELL | P14151 | 1/20 | 0.63 |
| ▸ | SELP | P16109 | 1/20 | 0.63 |
| ▸ | SELE | P16581 | 3/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29489964 | 1.00 | SIGLEC7 (0.68) | SIGLEC7MAGSELLSELPSELE | |
| SCHEMBL30649886 | 1.00 | SIGLEC7 (0.68) | SIGLEC7MAGSELLSELPSELE | |
| SCHEMBL30649376 | 1.00 | SIGLEC7 (0.68) | SIGLEC7MAGSELLSELPSELE | |
| SCHEMBL29532983 | 0.99 | SIGLEC7 (0.69) | SIGLEC7MAGSELLSELPSELE | |
| SCHEMBL31700997 | 0.98 | SIGLEC7 (0.68) | SIGLEC7MAGSELLSELPSELE | |
| SCHEMBL30536482 | 0.98 | SIGLEC7 (0.66) | SIGLEC7MAGSELLSELPSELE | |
| SCHEMBL29615731 | 0.98 | SIGLEC7 (0.70) | SIGLEC7MAGSELLSELPSELE | |
| SCHEMBL30970759 | 0.98 | SIGLEC7 (0.69) | SIGLEC7MAGSELLSELPSELE | |
| SCHEMBL18653452 | 0.98 | SIGLEC7 (0.67) | SIGLEC7MAGSELLSELPSELE | |
| SCHEMBL31700975 | 0.98 | SIGLEC7 (0.69) | SIGLEC7MAGSELLSELPSELE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260139285-A1 | SACCHARIDE IMPORTERS FOR LACTO-N-TRIOSE | INBIOSE N V (BE) | 2026-05-21 | — | — | US | disclosed |
| CN-122029274-A | Cell production of oligosaccharides comprising lacto-N-trisaccharide (LN 3) | 因比奥斯公司 | 2026-05-12 | — | — | CN | disclosed |
| US-20250361477-A1 | PRODUCTION OF AN OLIGOSACCHARIDE MIXTURE BY A CELL | INBIOSE NV (BE) | 2025-11-27 | — | — | US | disclosed |
| WO-2025224348-A1 | PRODUCTION OF A MILK OLIGOSACCHARIDE MIXTURE | INBIOSE N.V. (BE) | 2025-10-30 | — | — | WO | disclosed |
| US-12344875-B2 | Sialyltransferases for the production of sialylated oligosaccharides | INBIOSE N.V. (BE) | 2025-07-01 | — | — | US | disclosed |
| US-20250188503-A1 | SIALYLTRANSFERASES FOR THE PRODUCTION OF SIALYLATED OLIGOSACCHARIDES | INBIOSE N.V. (BE) | 2025-06-12 | — | — | US | disclosed |
| US-20250188504-A1 | PRODUCTION OF A MIXTURE OF MAMMALIAN MILK OLIGOSACCHARIDES BY A CELL | INBIOSE N.V. (BE) | 2025-06-12 | — | — | US | disclosed |
| US-20250109419-A1 | SIALYLTRANSFERASES FOR THE PRODUCTION OF SIALYLATED OLIGOSACCHARIDES | INBIOSE N.V. (BE) | 2025-04-03 | — | — | US | disclosed |
| US-20250043253-A1 | SIALYLTRANSFERASES FOR THE PRODUCTION OF SIALYLATED OLIGOSACCHARIDES | INBIOSE N.V. (BE) | 2025-02-06 | — | — | US | disclosed |
| US-20240417767-A1 | PRODUCTION OF ALPHA-1,3-FUCOSYLATED COMPOUNDS | INBIOSE N.V. (BE) | 2024-12-19 | — | — | US | disclosed |
| US-20240084347-A1 | CELLULAR PRODUCTION OF GLYCOSYLATED PRODUCTS | INBIOSE N.V. (BE) | 2024-03-14 | — | — | US | disclosed |
| US-20240035055-A1 | PROCESS FOR PURIFICATION OF AN OLIGOSACCHARIDE SOLUTION PRODUCED BY CELL CULTIVATION OR MICROBIAL FERMENTATION | INBIOSE N.V. (BE) | 2024-02-01 | — | — | US | disclosed |
| US-20240011062-A1 | METHOD TO PRODUCE A PURIFIED MIXTURE OF DIFFERENT OLIGOSACCHARIDES PRODUCED BY CELL CULTIVATION OR MICROBIAL FERMENTATION | INBIOSE N.V. (BE) | 2024-01-11 | — | — | US | disclosed |
| US-20230416796-A1 | PRODUCTION OF GALACTOSYLATED DI- AND OLIGOSACCHARIDES | INBIOSE N.V. (BE) | 2023-12-28 | — | — | US | disclosed |
| CN-117222736-A | Cellular production of biological products | 因比奥斯公司 | 2023-12-12 | — | — | CN | disclosed |
| CN-117157396-A | Cell production of sialylated di-and/or oligosaccharides | 因比奥斯公司 | 2023-12-01 | — | — | CN | disclosed |
| US-20230313252-A1 | CELLULAR PRODUCTION OF SIALYLATED DI AND/OR OLIGOSACCHARIDES | INBIOSE N.V. (BE) | 2023-10-05 | — | — | US | disclosed |
| CN-116783291-A | Cellular production of glycosylation products | 因比奥斯公司 | 2023-09-19 | — | — | CN | disclosed |
| US-20230287470-A1 | PRODUCTION OF OLIGOSACCHARIDE MIXTURES BY A CELL | INBIOSE N.V. (BE) | 2023-09-14 | — | — | US | disclosed |
| WO-2023285650-A1 | LACTO-N-BIOSE CONVERTING FUCOSYLTRANSFERASES | INBIOSE N.V. (BE) | 2023-01-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260139285-A1 | SACCHARIDE IMPORTERS FOR LACTO-N-TRIOSE | GALNT3, NANS, ENGASE | SIGLEC7 512/4885MAG 1618/4885SELL 599/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.